- Home
- ACAD vs APAM Comparison
ACAD vs APAM Comparison
Compare ACAD & APAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- APAM
- Stock Information
- Founded
- ACAD 1993
- APAM 1994
- Country
- ACAD United States
- APAM United States
- Employees
- ACAD N/A
- APAM 584
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- APAM Investment Managers
- Sector
- ACAD Health Care
- APAM Finance
- Exchange
- ACAD Nasdaq
- APAM Nasdaq
- Market Cap
- ACAD 4.0B
- APAM 3.3B
- IPO Year
- ACAD 2004
- APAM 2013
- Fundamental
- Price
- ACAD $25.99
- APAM $46.81
- Analyst Decision
- ACAD Buy
- APAM Hold
- Analyst Count
- ACAD 20
- APAM 6
- Target Price
- ACAD $28.63
- APAM $43.42
- AVG Volume (30 Days)
- ACAD 2.0M
- APAM 459.7K
- Earning Date
- ACAD 08-06-2025
- APAM 10-28-2025
- Dividend Yield
- ACAD N/A
- APAM 7.63%
- EPS Growth
- ACAD 615.00
- APAM 12.91
- EPS
- ACAD 1.33
- APAM 3.78
- Revenue
- ACAD $1,018,885,000.00
- APAM $1,136,529,000.00
- Revenue This Year
- ACAD $14.01
- APAM $7.21
- Revenue Next Year
- ACAD $11.72
- APAM $9.65
- P/E Ratio
- ACAD $19.61
- APAM $12.38
- Revenue Growth
- ACAD 14.41
- APAM 10.03
- 52 Week Low
- ACAD $13.40
- APAM $32.75
- 52 Week High
- ACAD $26.65
- APAM $49.54
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- APAM 53.13
- Support Level
- ACAD $25.14
- APAM $46.25
- Resistance Level
- ACAD $26.65
- APAM $48.46
- Average True Range (ATR)
- ACAD 0.67
- APAM 0.81
- MACD
- ACAD 0.04
- APAM 0.03
- Stochastic Oscillator
- ACAD 70.27
- APAM 57.25
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About APAM Artisan Partners Asset Management Inc.
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.